<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577197</url>
  </required_header>
  <id_info>
    <org_study_id>MUMC-MO-2015-01</org_study_id>
    <nct_id>NCT03577197</nct_id>
  </id_info>
  <brief_title>Southeast Netherlands Advanced Metastatic Breast Cancer Registry</brief_title>
  <acronym>SONABRE</acronym>
  <official_title>Southeast Netherlands Advanced Breast Cancer Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Ziekenhuis Maastricht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life
      multi-center study. The registry aims to include all patients diagnosed with advanced breast
      cancer as of 2007 in 14 hospitals in the Netherlands. Data on patient, tumor and treatment
      characteristics are collected retrospectively from electronic medical files by trained
      registry clerks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This SONABRE registry is an ongoing observational cohort study aiming at the inclusion of all
      patients aged â‰¥18 years and diagnosed with advanced breast cancer in 2007-2019 in 14
      hospitals in the Southeast of the Netherlands. Patients with de novo or recurrent advanced
      breast cancer were identified from the hospital-based management information systems.
      Specially trained registration clerks retrospectively collected data from the medical files
      of the patients based on extensive medical chart review. Information was collected about
      patient and tumour characteristics, type of treatment (surgery, radiotherapy and systemic
      treatment, both neo-adjuvant, adjuvant and palliative), palliative treatment changes due to
      adverse events, hospitalization, comorbidities and outcomes (progression and death). The
      SONABRE Registry has already been effectively used to perform real-life studies on safety and
      (cost-)effectiveness of various systemic treatments used in patients diagnosed with advanced
      breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2007</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Treatment pattern</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Treatment pattern per palliative treatment line; proportion of patients receiving chemotherapy, chemotherapy plus targeted therapy, endocrine therapy, endocrine therapy plus targeted therapy or targeted therapy alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Progression-free survival per systemic agent or palliative treatment line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICER</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Incremental cost-effectiveness ratio per QALY (quality-adjusted life year) gained of a new systemic drug compared with standard care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>upt to 13 years</time_frame>
    <description>Quality of life; health state utility score calculated from the EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Costs of advanced breast cancer care from a hospital perspective</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patient diagnosed with advanced breast cancer between 2007-2019 in 14
        hospitals in the Netherlands. No patients are being excluded. Also patients with no
        systemic / active antitumor therapy for advanced breast cancer will be included. The
        SONABRE Registry includes 14 hospitals: 1 academic, 7 teaching and 6 general hospitals. The
        Netherlands counts 114 hospitals, including 8 academic, 25 teaching, 58 general and 23
        categorical hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with de novo or recurrent advanced breast cancer in 2007-2019

          -  Diagnosed with or treated for advanced breast cancer in one of the participating
             hospitals

          -  Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2019), Zuyderland
             hospitals Sittard/Heerlen (2007-2019), Amphia Hospital Breda (2007-2019), Catharina
             Hospital Eindhoven (2007-2019), Elkerliek Hospital Helmond (2007-2019), Maxima Medical
             Center Veldhoven/Eindhoven (2010-2019), Jeroen Bosch Hospital Den Bosch (2007-2019),
             Laurentius Hospital Roermond (2007-2019), St. Annaziekenhuis Geldrop (2007-2019), St.
             Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2019), VieCuri
             Medical Center Venlo/Venray (2007-2014), all in the Netherlands.

          -  Hospitals (and periods) were eligible for inclusion if (distant) registration from
             Maastricht UMC+ was possible.

          -  Other hospitals will be added during the running phase of the study, and possibly the
             inclusion period may be prolonged after 2020.

        Exclusion Criteria: none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vivianne CG Tjan-Heijnen, MD, PhD</last_name>
    <phone>+31 (0) 43 3877025</phone>
    <email>vcg.tjan.heijnen@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra ME Geurts, PhD</last_name>
    <phone>+31 (0) 43 3875217</phone>
    <email>sandra.geurts@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Multiple hospitals in the Netherlands (see Eligibility)</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivianne CG Tjan-Heijnen, MD, PhD</last_name>
      <phone>+31 (0) 43 3877025</phone>
      <email>vcg.tjan.heijnen@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015 Apr 28;112(9):1445-51. doi: 10.1038/bjc.2015.127. Epub 2015 Apr 16.</citation>
    <PMID>25880008</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.</citation>
    <PMID>24104881</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobbezoo D, Truin W, Voogd A, Roumen R, Vreugdenhil G, Dercksen MW, van den Berkmortel F, Smilde T, van de Wouw A, van Kampen R, van Riel J, Peters N, Peer P, Tjan-Heijnen VC. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. Oncotarget. 2016 May 17;7(20):29412-9. doi: 10.18632/oncotarget.8838.</citation>
    <PMID>27121067</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016 Feb;27(2):256-62. doi: 10.1093/annonc/mdv544. Epub 2015 Nov 16.</citation>
    <PMID>26578730</PMID>
  </results_reference>
  <results_reference>
    <citation>van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, de Boer M, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FPJ, van Riel JMG, Peters NAJB, Tjan-Heijnen VCG, Joore MA. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. Eur J Cancer. 2017 Jul;79:238-246. doi: 10.1016/j.ejca.2017.01.027. Epub 2017 Feb 27.</citation>
    <PMID>28245951</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>November 3, 2019</last_update_submitted>
  <last_update_submitted_qc>November 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Ziekenhuis Maastricht</investigator_affiliation>
    <investigator_full_name>V.C.G. Tjan-Heijnen</investigator_full_name>
    <investigator_title>Professor of medical oncology</investigator_title>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

